SPRY Earnings Date 2026
ARS Pharmaceuticals, Inc earnings schedule and quarterly results
Next Earnings Date
TBD
Current Stock Price
$5.77
+0.00% today
Earnings Metrics
EPS (TTM)
$0.08
P/E Ratio
72.1
Revenue Growth
297063.3%
Market Cap
$1.0B
Earnings History
| Quarter | EPS | Revenue | Net Income |
|---|---|---|---|
| Q4 2024 | $0.08 | $0.09B | $0.01B |
| Q4 2023 | $-0.57 | $0.00B | $-0.05B |
Trading Around SPRY Earnings
Before Earnings
- Review analyst expectations and consensus estimates
- Check options implied volatility for expected move
- Consider historical earnings surprises
- Monitor pre-announcement guidance
After Earnings
- Compare actual results to estimates
- Listen to the earnings call for guidance
- Watch for analyst rating changes
- Monitor institutional buying/selling
Get Full SPRY Analysis
DCF valuation, AI insights, and institutional ownership data
Frequently Asked Questions
When is SPRY next earnings date?
SPRY (ARS Pharmaceuticals, Inc) has not yet announced its next earnings date. Check back for updates on the upcoming earnings schedule.
What is SPRY earnings per share (EPS)?
SPRY's current earnings per share (EPS) is $0.08. With a P/E ratio of 72.1, the market values each dollar of earnings at $72.1.
How often does SPRY report earnings?
Like most publicly traded US companies, SPRY (ARS Pharmaceuticals, Inc) reports earnings quarterly, typically within 4-6 weeks after each fiscal quarter ends. The company holds an earnings call to discuss results with analysts.
What time does SPRY report earnings?
SPRY typically reports earnings either before market open (BMO) or after market close (AMC). The exact time is usually announced a few days before the earnings date. Check the investor relations page for specific timing.
How has SPRY performed in recent earnings?
In the most recent quarter (Q4 2024), SPRY reported EPS of $0.08 on revenue of $0.09B.
What do analysts expect for SPRY earnings?
Analyst expectations for SPRY earnings can vary. The company has shown positive revenue growth of 297063.3%. View the full analyst ratings page for detailed expectations.